By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer's disease in a recent proof-of-concept clinical trial.
http://eon.businesswire.com/news/eon/20130409005200/en/Cognoptix-reaches-halfway-point-pre-pivotal-clinical-trial
http://eon.businesswire.com/news/eon/20130409005200/en/Cognoptix-reaches-halfway-point-pre-pivotal-clinical-trial
No comments:
Post a Comment